Anticorpos Monoclonais/farmacologia; Anticorpos Monoclonais/farmacocinética; Anticorpos Neutralizantes/farmacologia; Sistemas de Liberação de Medicamentos; Subunidade p19 da Interleucina-23/antagonistas & inibidores; Animais; Anticorpos Monoclonais/imunologia; Anticorpos Neutralizantes/imunologia; Doença de Crohn/tratamento farmacológico; Doença de Crohn/imunologia; Humanos; Subunidade p19 da Interleucina-23/imunologia; Macaca fascicularis; Psoríase/tratamento farmacológico; Psoríase/imunologia; Células Th17/imunologia

ADCC, antibody-dependent cell-mediated cytotoxicity; AUC, analytical ultracentrifugation; BI 655066; CCG, Chemical Computing Group; CDRs, complementarity-determining regions; CH, constant region; Cκ, constant kappa; DMF, dimethylformamide; EOF, electro-osmotic flow; ESI, electrospray ionization; F, phenylalanine; G, glycine; GAHA, goat anti-human IgG gamma antibody; HCLF, high concentration liquid formulation; IL12, Interleukin 12; IL12RB1, IL12 receptor subunit beta 1; IL23, Interleukin-23; IL23R, IL23 receptor; JAK2, Janus kinase 2; PBS, phosphate-buffered saline; PK, pharmacokinetic; RU, resonance units; SEC, size-exclusion chromatography; SPR, surface plasmon resonance; Th17, T helper 17 cells; UV, ultraviolet; V, variable; VH, variable heavy; Vκ, variable kappa; Y, tyrosine; biophysical assessment; humanization; immunogen design; pharmacokinetic profile; tyk2, tyrosine kinase 2